Freenome

Today, biopsies and scans aren’t the only ways to detect cancer; tumors also shed DNA, RNA, and proteins that can be detected in the bloodstream. Freenome is developing multiomics tests that use machine learning to detect complex patterns in both tumor-derived and non-tumor-derived biomarkers, making it possible to diagnose cancers earlier, when they’re more treatable. The company began with a blood-based test for colorectal cancer and is preparing for large studies of tests for multiple cancers.